Department of Internal Medicine, Section Hematology, Maastricht University Medical Center+, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands; School for Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, the Netherlands.
Department of Internal Medicine, Section Hematology, Maastricht University Medical Center+, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands; School for Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, the Netherlands.
J Clin Epidemiol. 2022 Aug;148:10-16. doi: 10.1016/j.jclinepi.2022.03.012. Epub 2022 Mar 26.
The MOSA study (Maastricht Observational study of late effects after Stem cell trAnsplantation) aims to study the prevalence of adverse health effects in hematopoietic stem cell transplantation (HCT) survivors compared to a matched cohort, representing the general population.
The MOSA study is a matched cohort study, nested within a large prospective cohort, The Maastricht Study. Participants of The Maastricht Study serve as a reference group matched on age, gender, and education to compare MOSA participants to the general population. In both studies, the same study protocol and extensive phenotyping measurements are used.
HCT Survivors: Five hundred and thirty nine survivors were invited of which, so far, 123 (23%) participants completed the study assessments. Data will be analyzed and published separately. Reference Group: For each MOSA participant, four reference cases were matched. After matching, both groups are comparable with respect to age, gender, and education.
To our knowledge, this is the first study conducting such detailed phenotyping in HCT survivors. Comparison with a large reference group provides essential information about late effects of HCT and associated risk factors. This may improve screening and prevention strategies, potentially leading to a positive impact on morbidity, mortality, and quality of life.
MOSA 研究(骨髓移植后晚期效应的马斯特里赫特观察研究)旨在研究造血干细胞移植(HCT)幸存者与匹配队列(代表一般人群)相比不良健康影响的患病率。
MOSA 研究是一项匹配队列研究,嵌套在大型前瞻性队列 Maastricht 研究中。Maastricht 研究的参与者作为参考组,按年龄、性别和教育与 MOSA 参与者进行匹配,以将他们与一般人群进行比较。在这两项研究中,都使用相同的研究方案和广泛的表型测量。
HCT 幸存者:共邀请了 539 名幸存者,迄今为止,已有 123 名(23%)参与者完成了研究评估。数据将单独进行分析和发布。参考组:对于每一位 MOSA 参与者,都匹配了四个参考病例。匹配后,两组在年龄、性别和教育方面具有可比性。
据我们所知,这是第一项在 HCT 幸存者中进行如此详细表型研究的研究。与大型参考组进行比较,提供了关于 HCT 晚期效应及其相关危险因素的重要信息。这可能会改善筛查和预防策略,从而对发病率、死亡率和生活质量产生积极影响。